After treatment with 5 mg/kg/day SH-1028, a moderate tumor growth inhibition was observed in A431 (wild-type EGFR) tumor xenografts, suggesting that SH-1028 and its metabolites are not entirely inactive against tumor cells with wild-type EGFR. This evidence concerns the gene EGFR and neoplasm.